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The aim of the present study was to investigate whether long-term exposure to valproate (VPA) alters follicular steroidogenesis
and whether or not this effect is dependent on the degree of follicular development. Small- and medium-sized follicles were
obtained from pig ovaries collected, respectively, at days 8–10 and 14–16 of oestrus cycle. Theca interna and granulosa cells
were isolated from follicles and placed in the same well in the ratio 1 : 3 with or without the VPA in doses of 100, 300 and
500 µg ml−1. The culture medium was changed after 2, 4, 6 and 8 days. In both types of follicles, VPA caused a signifi-
cant and dose-dependent reduction in both testosterone and estradiol secretion from follicular cells. In small-sized follicles,
the testosterone to oestrogen ratio increased at all doses used and after all lengths of time in culture. In medium-sized folli-
cles, a significant increase in the testosterone to oestrogen ratio was only observed at the highest dose level. All doses of VPA
caused a marked inhibition of progesterone secretion after 48 hours while during long-term VPA exposure progesterone grad-
ually increased demonstrating luteinization of cells. In conclusion, the present study demonstrates a direct effect of VPA on
steroidogenesis. The effect seems to differ to some extent depending on the follicular stage of development. The elevated ratio
of testosterone to estradiol suggests that VPA inhibits the conversion of testosterone to estradiol.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Valproate (VPA) is a major antiepileptic drug with a
broad spectrum of antiepileptic activity. It has been
the drug of choice in the treatment of most forms
of primary generalized epilepsies and is also efficient
against partial seizures1–3. There is, however, increas-
ing concern about the possible effects of antiepilep-
tic drugs, especially VPA, on reproductive endocrine
function4–13. In 1981, Margraff and Dreifuss14 were
the first to report amenorrhoea as a side effect of VPA.
This has later been confirmed in a series of stud-
ies from Isoja¨rvi and coworkers6–8 who found men-
strual disorders, polycystic ovaries and/or hyperandro-
genism in as many as 60% of women receiving chronic
VPA treatment. These changes were partially re-
versible by replacing VPA with lamotrigine indicating
a drug-specific effect9. In accordance with this, Muri-
aldo et al.11, 12 showed that in epilepsy patients receiv-
ing VPA as part of a polytherapy regimen, 40% devel-
oped polycystic ovaries while 63.5% of all patients on
VPA had elevated serum androgen levels and hyperan-
drogenic anovulation. Estradiol levels were lower than
in healthy controls in the follicular phase12.
Folliculogenesis is disturbed in patients with poly-
cystic ovary syndrome (PCOS)15. The initial steps,
recruitment and growth of the small Graafian stages,
are functional in PCOS, but the selection of domi-
nant follicles to be ovulated does not occur regularly.
This leads to accumulation of a large number of small
Graafian follicles (commonly referred to as cysts) in
which the theca interstitial cells produce abnormally
large amounts of androgen while the granulosa cells
fail to aromatize the androgen substrate to estradiol.
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It has also been recently shown in non-epileptic rats
that VPA induces polycystic ovaries and changes in
peripheral sex steroid hormone levels, pointing to a
drug-specific effect on endocrine function indepen-
dent of epileptic activity16, 17. The question then arises
whether this is a centrally mediated effect or a direct
effect of the drug on folliculogenesis and steroid hor-
mone secretion in the ovary. The aim of the present
study was first to investigate the possibility of a direct
effect of VPA on follicular cells and then to investi-
gate whether this effect was dependent upon follicular
development.
MATERIALS AND METHODS
Reagents
Parker medium (M199), calf serum, trypsin and PBS
were obtained from Biomed, Lublin, Poland. Antibi-
otic antimycotic solution (1%) was obtained from
Sigma Chemical Co., St Louis, MO, USA. Sodium
valproate (VPA) was a gift from Desitin Pharma, Nor-
way.
Cell cultures
Porcine ovaries obtained from a local abattoir were
collected into a bottle filled with sterilized ice-cold
saline and transported to the laboratory. Approxi-
mately 1.5 h elapsed from slaughter to collection in
the laboratory. Small- and medium-sized follicles were
obtained from ovaries collected, respectively, at days
8–10 and 14–16 of the oestrus cycle as described pre-
viously18, 19. Granulosa cells (Gc) and theca interna
cells (Tc) were subsequently prepared.
The separation of Gc from the theca layer was per-
formed according to the technique described by Stok-
losowa et al.20. Gc were scraped from the follicular
wall with round-tipped ophthalmologic tweezers and
rinsed several times with PBS. After collection, gran-
ulosa cells were washed three times in M199 con-
taining 100 IU ml−1 penicillin and 1 mg ml−1 nys-
tatin, and were recovered by centrifugation (10 min at
200 g). The theca cells from the same follicles were
prepared as previously described in detail by Stok-
losowa et al.20. Briefly, the theca layers were placed in
a drop of saline under the dissection microscope. The
theca interna was manually separated from the under-
lying theca externa. The isolated theca interna tissue
was then washed, cleaned, cut with scissors and trypsi-
nated with 6–7 ml 0.25% trypsin in PBS for 10 min
at 37 ◦C. The cells were separated by decanting. This
procedure was repeated three times.
The cell viability, determined using the trypan blue
exclusion test, was 85% for theca cells and 92% for
granulosa cells. The average yield of granulosa cells
was 5.0× 105 cells ml−1 for small-sized follicles and
0.7× 106 cells ml−1 for medium-sized follicles.
In co-culture experiments, 1 ml each of suspended
Gc and Tc cells were placed in the same well giving
a total of 2 ml of culture medium per well. Theca-
derived androgens served as a substrate for produc-
tion of estradiol by Tc cells in co-culture with Gc. The
cultures were maintained at 37 ◦C in a humidified at-
mosphere of 5% CO2/95% O2. Cells were cultured in
Parker Medium (M199) supplemented with 10% calf
serum with or without added VPA in doses of 100, 300
and 500 µg ml−1. The culture medium was changed
after 48, 96, 144 and 192 hours and the collected me-
dia were stored at−20 ◦C until steroid analysis. Every
treatment was conducted in five wells and each exper-
iment was repeated three times.
Steroid analysis
Testosterone (T), 17β-estradiol (E2) and proges-
terone (P4) levels were determined by radioimmunol-
ogy using Spectra kits (Orion, Diagnostica, Finland),
supplied by Polatom (wierk, Poland).
For testosterone, the limit of the assay sensitivity
was 5 pg ml−1. The coefficients of variation within
and between assays were 5.4% and 5.3%, respectively.
The mean recoveries were 84.2–121.7%. The cross-
reaction with 5α-dihydrotestosterone was 4.5%. All
other tested steroids (methyltestosterone, androsten-
dione, progesterone, 17β-estradiol) showed less than
0.5% cross-reaction.
For 17β-estradiol, the detection limit of assay was
5 pg. The coefficients of variation between and within
assays were 10.28% and 2.9%, respectively. The mean
recoveries were 85.6–108.9%. The cross-reaction with
ethinylestradiol was 1.4%. All other tested steroids
(estrone, estriol, progesterone, testosterone, corticos-
terone) showed less than 1% cross-reaction.
For progesterone, the assay sensitivity was
94 pg ml−1. The coefficients of variation between
and within assays were 5.8% and 2.9%, respec-
tively. The mean recoveries were 95.1–103.7%. The
cross-reaction with pregnenolone was 2.9%. All
other tested steroids (5β-dihydroprogesterone, 20β-
hydroxyprogesterone, corticosterone, testosterone, es-
trone) showed less than 1% cross-reaction.
Statistical analysis
All data points are expressed as means ± SEM from at
least three different experiments (n = 3), each in quin-
tuple. The significance of differences between the con-
centrations of progesterone, estradiol and testosterone
in the control and experimental cultures were com-
pared by analysis of variance and by Duncan’s new
multiple range test.
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Fig. 1: Testosterone (T), estradiol (E2) and progesterone (P4) secretion by control (C) and VPA-treated cells isolated from small
follicles over (a) 2, (b) 4, (c) 6 and (d) 8 days of culture.
RESULTS
Small follicles
In the control culture, follicular cells secreted 26.1,
36.5, 37.3 and 37.9 ng ml−1 of testosterone, respec-
tively, after 2, 4, 6 and 8 days. The amount of estra-
diol secreted into the culture medium did not change
during the study and was approximately 10 ng ml−1
(Fig. 1(a)–(d)). The ratio of testosterone to oestrogen
in the control culture was 2.6 after 2 days of culture
and then 3.4 after 4, 6 and 8 days of culture.
VPA added to the culture medium caused a sig-
nificant and dose-dependent reduction in both testos-
terone and estradiol secretion from follicular cells. The
ratio of testosterone to oestrogen increased depending
on the doses used and the length of time in culture.
After 2 days of culture with VPA, the testosterone to
oestrogen ratio was 3.1, 4.6 and 5.5, respectively, for
100, 300 and 500 µg VPA ml−1 medium. This change
towards an increased testosterone to oestrogen ratio
was observed after all lengths of culture (Fig. 1(a)–
(d)).
Exposure to all doses of VPA caused a marked
inhibition of progesterone secretion after 2 days
(Fig. 1(a)). However, during long-term VPA expo-
sure progesterone gradually increased demonstrating
luteinization of cells. Compared to the progesterone
level at day 2, the progesterone levels at days 4, 6 and
8 increased by a factor of 1.4, 1.6 and 1.8, respectively,
in control cells not exposed to VPA. Corresponding
values for VPA-treated cells were 6.6, 8.0 and 8.9 us-
ing a dose of 100 µg ml−1; 7.0, 10 and 10.7 after a
dose of 300 µg ml−1 and 3.5, 4.9 and 4.9 after a dose
of 500 µg ml−1.
Medium follicles
In the control culture, follicular cells secreted 26.4,
30.1, 33.2 and 33.5 ng ml−1 of testosterone, respec-
tively, after 2, 4, 6 and 8 days. A higher amount of
estradiol secreted by this type of follicle was observed
(42.9, 46.3, 46.7 and 47.2 ng ml−1, respectively, after
2, 4, 6 and 8 days of culture) (Fig. 2(a)–(d)). The ra-
tio of testosterone to oestrogen in the control culture
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Fig. 2: Testosterone (T), estradiol (E2) and progesterone (P4) secretion by control (C) and VPA-treated cells isolated from medium
follicles over (a) 2, (b) 4, (c) 6 and (d) 8 days of culture.
was 0.67 and did not change during the study. VPA in
a dose of 100 µg ml−1 did not change the testosterone
to oestrogen ratio. After a dose of 300 µg ml−1 the ra-
tio of testosterone to oestrogen was 1 during all days
of culture, while after a dose of 500 µg ml−1 the ratios
were 1.6, 1.8, 2 and 2.7, respectively, after 2, 4, 6 and
8 days of culture.
VPA inhibited progesterone secretion compared to
control at all doses used and at all investigated days of
culture. As in the small follicles, luteinization was ob-
served during long-term exposure in both control cells
and VPA-treated cells by steadily increasing proges-
terone levels. In the control culture, progesterone in-
creased by a factor of 1.42, 1.6 and 1.9, respectively,
at days 4, 6 and 8 compared to the progesterone level
at day 2. In VPA-treated cells, progesterone increased
by a factor of 2.0, 2.4 and 3.0 after 100 µg ml−1; 1.8,
1.9 and 2.6 after 300µg ml−1 and 1.8, 2.3 and 2.8 after
500µg ml−1, respectively, at days 4, 6 and 8 compared
to the progesterone level at day 2.
DISCUSSION
The presented data clearly show that VPA has a di-
rect effect on follicular steroidogenesis. In small fol-
licles, which produce small amounts of estradiol and
have low P450 aromatase activity, VPA decreased both
testosterone and estradiol secretion while the ratio of
testosterone to oestrogen increased. In medium-sized
follicles with a higher aromatization capacity, the ra-
tio of testosterone to oestrogen also increased after a
VPA concentration of 500 µg ml−1, changing the ra-
tio towards testosterone secretion.
Our data, showing a direct effect of VPA on testos-
terone secretion from follicular cells, are supported
by observations of Elias et al.21, Melis et al.22, Lado
Abeal et al.23 and Isoja¨rvi et al.6, 7 which show that
women receiving VPA had normal serum LH levels
with normal LH responses to GnRH. The effect of
VPA on ovarian endocrine function can thus be ex-
plained by a direct effect upon the ovary, although an
additional, centrally mediated effect cannot be totally
excluded.
484 E. Gregoraszczuk et al.
Tamura et al.24 demonstrated that the granulosa
cells of PCOS follicles were mainly negative for
P450 aromatase which would reduce the conversion of
testosterone to oestrogen. In accord with this, Iso¨jarvi
et al.6 showed that serum estradiol concentrations
were not elevated in VPA-treated women despite el-
evated serum testosterone concentrations, suggesting
that VPA inhibited the conversion of testosterone to
estradiol. This gains further support from the observa-
tions of lower estradiol levels in VPA-treated women
vs. healthy controls studied in the follicular phase12.
Elevation of the testosterone to estradiol ratio, as
demonstrated in our study, suggests that VPA inhibits
the conversion of testosterone to estradiol. The most
likely explanation for this finding is thus an inhibition
of P450 aromatase activity by VPA treatment.
In a study of endocrine effects of chronic VPA treat-
ment in rats, Taubøll et al.16 showed a significantly
increased number of follicular cysts together with re-
duced testosterone and a trend towards reduced oe-
strogen levels after 3 months. The testosterone to oe-
strogen ratio was unchanged between controls and
animals receiving either 50 or 200 mg kg−1 day−1
of VPA. Serum VPA concentrations were 72 and
200 µmol l−1 in the two treatment groups which are
actually below therapeutic range in humans. In a sim-
ilar long-term study using higher VPA doses of 400
and 600 mg kg−1 day−1 with serum concentrations
well within therapeutic range, the same group demon-
strated a marked increase in the testosterone to oestro-
gen ratio in accordance with our findings25. It may
thus be that the effect of VPA on P450 aromatase
activity is more pronounced at higher serum concen-
trations. In the present study, the VPA concentrations
used ranged from the therapeutic range (100 µg ml−1)
and upwards. However, it must be kept in mind that the
so-called therapeutic range in humans represents min-
imum concentrations as trough morning levels. It is
well known that due to the kinetics of the drug, diurnal
fluctuations in the range of several hundred percent oc-
cur also in humans26, 27. Further, the effects of VPA on
the secretion of hormones from follicular cells in our
study was, except for a degree of magnitude, indepen-
dent of VPA concentrations and still significant at the
lowest concentration used, which was within the ther-
apeutic range for humans. We therefore consider our
findings of clinical relevance for chronic VPA treat-
ment in epilepsy patients.
The presented data clearly showed decreased pro-
gesterone secretion after short-term VPA treatment.
Although data on progesterone production from follic-
ular cells in women with PCOS is limited, our finding
gains some support from the study of Erickson et al.15
which demonstrated reduced progesterone production
from granulosa cells in women with PCOS. Reduced
progesterone secretion was also observed in follicular
cells from women with PCOS following gonadotropin
hyperstimulation28. On the other hand, Gilling-Smith
et al.29 and Willis et al.30 suggested increased basal
progesterone levels in anovulatory PCOS. This in-
crease in basal progesterone levels has been suggested
to be due to an abnormal regulation of P450c17α func-
tion which may explain the hyperandrogenic func-
tion31.
In conclusion, the present study suggests a direct
effect of VPA on ovarian endocrine function. Our
data thus support previous findings in humans6–9 and
recent studies in non-epileptic rats16, 17, 25 showing
changes in ovarian morphology and endocrinology af-
ter chronic VPA treatment.
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